Evaluation of the reinforcing and discriminative stimulus properties of the low-affinity N-methyl-D-aspartate channel blocker memantine

Behavioural Pharmacology

Volumn 9, Issue 3, 1998, Pages 231-243

  Nicholson, K L ^a   Jones, H E ^a   Balster, R L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amantadine; Drug discrimination; Memantine; Monkey; NMDA receptor; Phencyclidine; Rat; Self administration

Indexed keywords

AMANTADINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG ACTIVITY; DRUG DISCRIMINATION; DRUG EFFECT; DRUG SCREENING; DRUG SELF ADMINISTRATION; FOOD INTAKE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; RAT; REINFORCEMENT; RHESUS MONKEY;

AMANTADINE; ANIMALS; DISCRIMINATION (PSYCHOLOGY); DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; MACACA MULATTA; MALE; MEMANTINE; PHENCYCLIDINE; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION;

EID: 0031779010     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Ambrozi L, Danielczyk W (1988). Treatment of impaired cerebral function in psychogeriatric patients with memantine - results of a phase II double-blind study. Pharmacopsychiatry 21:144-146.
2. Balster RL (1991a). Discriminative stimulus properties of phencyclidine and other NMDA antagonists. In Glennon RA, Järbe TUC and Frankenheim J, editors. Drug discrimination: applications to drug abuse research. National Institute on Drug Abuse Research Monograph Series 116, DHHS Publication no. (ADM) 92-1878. Washington, DC: US Government Printing Office. pp. 163-180.
3. Balster RL (1991b). Drug abuse potential evaluation in animals. Br J Addiction 86:1549-1558.
4. Balster RL, Johanson CE, Harris RT, Schuster CR (1973). Phencyclidine self-administration in the rhesus monkey. Pharmacol Biochem Behav 1:167-172.
5. Balster RL, Nicholson KL, Sanger DJ (1994). Evaluation of the reinforcing effects of eliprodil in rhesus monkeys and its discriminative stimulus effects in rats. Drug Alcohol Depend 35:211-216.
6. Balster RL, Mansbach RS, Shelton KL, Nicholson KL, Grech DM, Wiley JL et al. (1995). Behavioral pharmacology of two novel substituted quinoxalinedione glutamate antagonists. Behav Pharmacol 6:577-589.
7. Barnes CA, Danysz W, Parsons CG (1996). Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 8:565-571.
8. Beardsley PM, Hayes BA, Balster RL (1990). The self-administration of MK-801 can depend upon drug-reinforcement history, and its discriminative stimulus properties are phencyclidine-like in rhesus monkeys. J Pharmacol Exp Ther 252:953-959.
9. Benveniste H, Drejer J, Schousboe A, Diemer NH (1984). Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 43:1369-1374.
10. Bisaga A, Krzascik P, Janowska E, Palejko W, Kostowski W, Danysz W (1993). Effect of glutamate receptor antagonists on N-methyl-D-aspartate and (S)-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-induced convulsant effects in mice and rats. Eur J Pharmacol 242:213-220.
11. Bobelis DJ, Balster RL (1993). Pharmacological specificity of the discriminative stimulus properties of 2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid (NPC 12626), a competitive N-methyl-D-aspartate receptor antagonist. J Pharmacol Exp Ther 264:845-853.
12. Bormann J (1989). Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 166:591-592.
13. Botez MI, Botez-Marquard T, Elie R, Pedraza O-L, Goyette K, Lalonde R (1996). Amantadine hydrochloride treatment in heterodegenerative ataxias: a double blind study. J Neurol Neurosurg Psychiatry 61:259-264.
14. Brady KT, Balster RL, May EL (1982a). Stereoisomers of N-allylnormetazocine: Phencyclidine-like behavioral effects in squirrel monkeys and rats. Science 215:178-180.
15. Brady KT, Woolverton WL, Balster RL (1982b). Discriminative stimulus and reinforcing properties of etoxadrol and dexoxadrol in monkeys. J Pharmacol Exp Ther 220:56-62.
16. Browne RG (1982). Discriminative stimulus properties of PCP. In Colpaert FC, Slangen JL, editors. Drug discrimination: applications in CNS pharmacology. Amsterdam: Elsevier. pp. 109-122.
17. Bresink I, Danysz W, Parsons CG, Mutschler E (1995). Different binding affinities of NMDA receptor channel blockers in various brain regions - indication of NMDA receptor heterogeneity. Neuropharmacology, 34:533-540.
18. Carlsson M, Carlsson A (1990). Systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci 13:272-276.
19. Chen H-SV, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA (1992). Open-channel block of the N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA-receptor mediated neurotoxicity. J Neurosci 12:4427-4436.
20. Clements JD, Lester RAJ, Tong G, Jahr CE, Westbrook GL (1992). The time course of glutamate in the synaptic cleft. Science 258:1498-1501.
21. Danysz W, Zajaczkowski W, Parsons CG (1995). Modulation of learning processes by ionotropic glutamate receptor ligands. Behav Pharmacol 6:455-474.
22. Dimpfel W (1995). Effects of memantine on synaptic transmission in the hippocampus in vitro. Arzneim Forsch/ Drug Res 45:1-5.
23. Ditzler K (1991). Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneim Forsch/Drug Res 41:773-780.
24. Fleischhacker WW, Buchgeher A, Schubert H (1986). Memantine in the treatment of senile dementia of the Alzheimer type. Prog Neuro-Psychopharmacol Biol Psychiatry 10:87-93.
25. Ferkany JW, Kyle DJ, Willetts J, Rzeszotarski WJ, Guzewska ME, Ellenberger SR, et al. (1989). Pharmacological profile of NPC 12626, a novel, competitive N-methyl-D-aspartate receptor antagonist. J Pharmacol Exp Ther 250:100-109.
26. France CP, Moerschbaecher JM, Woods JH (1991). MK-801 and related compounds in monkeys: discriminative stimulus effects on a conditional discrimination. J Pharmacol Exp Ther 257:727-733.
27. Frankiewicz T, Potier B, Bashir ZI, Collingridge GL, Parsons CG (1996). Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br J Pharmacol 117:689-697.
28. Görtelmeyer R, Erbler H (1992). Memantine in the treatment of mild to moderate dementia syndrome. Arzneim Forsch/ Drug Res 42:904-913.
29. Holtzman SG (1980). Phencyclidine-like discriminative effects of opioids in the rat. J Pharmacol Exp Ther 214:614-619.
30. Holtzman SG (1982). Phencyclidine-like discriminative stimulus properties of opioids in the squirrel monkey. Psychopharmacology 77:295-300.
31. Honneger UE, Quack G, Wiesmann UN (1993). Evidence for lysosomotropism of memantine in cultured human cells: cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and β-adrenergic transmission. Pharmacol Toxicol 73:202-208.
32. Jackson A, Sanger DJ (1988). Is the discriminative stimulus produced by phencyclidine due to an interaction with N-methyl-oaspartate receptors? Psychopharmacology 96:87-92.
33. Johanson CE, Balster RL (1978). A summary of the results of a drug self-administration study using substitution procedures in rhesus monkeys. Bull Narcotics 3:43-54.
34. Jones HE, Li H, Balster RL (1998) Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys. Pharmacol Biochem Behav 59:413-418.
35. Koek W, Colpaert FC (1990). Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencyclidine-like behavioral effects. J Pharmacol Exp Ther 252:349-357.
36. Kornhuber J, Weller M (1993). Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. J Neural Transmis (GenSect) 92:57-65.
37. Kornhuber J, Bormann J, Retz W, Hübers M, Riederer P (1989). Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166:589-590.
38. Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P (1991). Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-recpeptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 206:297-300.
39. Mansbach RS, Balster RL (1991). Pharmacological specificity of the phencyclidine discriminative stimulus in rats. Pharmacol Biochem Behav 39:971-975.
40. Meldrum BS, Turski L, Schwarz M, Czuczwar SJ, Sontag K-H (1986). Anticonvulsant action of 1,3-dimethyl-5-aminoadamantane: pharmacological studies in rodents and baboons, Papio papio. Naunyn-Schmiedeherg's Arch Pharmacol 332:93-97.
41. Moryl E, Danysz W, Quack G (1993). Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 72:394-397.
42. Parsons CG, Gruner R, Rozental J, Millar J, Lodge D (1993). Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantane). Neuropharmacology 32:1337-1350.
43. Parsons CG, Krishtal OA, Misgeld U (1994). Comparative-studies on NMDA receptor antagonism by amantadine (1-amino-adamantane) and memantine (1-amino-3,5-dimethyladamantane). Soc Neurosci Abstr 20:1144.
44. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, et al. (1995). Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34:1239-1258.
45. Parsons CG, Panchenko VA, Pinchenko VI, Tsyndrenko AY, Krishtal OA (1996). Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 8:446-454.
46. Porter RHP, Greenamyre JT (1995). Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 64:614-623.
47. Pradhan SN (1984). Phencyclidine (PCP): some human studies. Neurosci Biobehav Rev 8:493-501.
48. Rabey JM, Nissipeanu P, Korczyn AD (1992). Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transmis (P-D Sect) 4:277-282.
49. Riederer P, Lange KW, Kornhuber J, Danielczyk W (1991). Pharmacotoxic psychosis after memantine in Parkinson's disease. Lancet 338:1022-1023.
50. Sanger DJ, Terry P, Katz JL (1992). Memantine has phencyclidine-like but not cocaine-like discriminative stimulus effects in rats. Behav Pharmacol 3:265-268.
51. Sannerud CA, Griffiths RR (1988). Amantadine: evaluation of reinforcing properties and effect on cocaine self-injection in baboons. Drug Alcohol Depend 21:195-202.
52. Schechter MD (1977). Amphetamine discrimination as a test for anti-Parkinsonism drugs. Eur J Pharmacol 44:51-56.
53. Seif el Nasr M, Peruche B, Robberg C, Mennel H-D, Krieglstein J (1990). Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol 185, 19-24.
54. Singh L, Menzies R, Tricklebank MD (1990). The discriminative stimulus properties of (+)-HA-966, an antagonist at the glycine/N-methyl-D-aspartate receptor. Eur J Pharmacol 186:129-132.
55. Slifer BL, Balster RL (1983). Reinforcing properties of stereoisomers of the putative sigma agonists n-allylnor-metazocine and cyclazocine in rhesus monkeys. J Pharmacol Exp Ther 225:522-528.
56. Slifer BL, Balster RL (1985). Phencyclidine-like discriminative stimulus properties of the stereoisomers of dioxadrol. Subst Alcohol Actions/Misuse 5:273-280.
57. Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD (1989). The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 167:127-135.
58. Weiler M, Finiels-Marlier F, Paul SM (1993). NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. Brain Res 613:143-148.
59. Wenk GL, Danysz W, Mobley SL (1995). MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol 293:267-270.
60. Wesemann W, Sturm G, Fünfgeld EW (1980). Distribution and metabolism of the potential anti-Parkinson drug memantine in the human. J Neural Transmis 16 (suppl): 143-148.
61. Wiley JL, Balster RL (1994). Effects of competitive and noncompetitive N-methyl-D-aspartate (NMDA) antagonists in squirrel monkeys trained to discriminate d-CPPene (SDZ EAA 494) from vehicle. Psychopharmacolagy 116:266-272.
62. Willetts J, Balster RL (1988). The discriminative stimulus effects of N-methyl-D-aspartate antagonists in phencyclidine-trained rats. Neuropharmacology 27:1249-1256.
63. Willetts J, Balster RL, Leander JD (1990). The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacolog Sci 11: 423-428.
64. Witkin JM, Brave S, French D, Geter-Douglass B (1995). Discriminative stimulus effects of the R-(+)-3-amino-1-hydroxypyrrolid-2-one, [(+)-HA-966], a partial agonist of the strychnine-insensitive modulatory site of the N-methyl-D-aspartate receptor. J Pharmacol Exp Ther 275:1267-1273.
65. Young AM, Woods JH (1981). Maintenance of behavior by ketamine and related compounds in rhesus monkeys with different self-administration histories. J Pharmacol Exp Ther 218:720-727.
66. Young AM, Herling S (1986). Drugs as reinforcers: studies in laboratory animals. In: Behavioral analysis of drug dependence. Goldberg SR, Stolerman IP (editors). Orlando FL: Academic Press. pp. 9-67.
67. Zajaczkowski W, Moryl E, Papp M (1996a). Discriminative stimulus effects of the NMDA receptor antagonists MK-801 and CGP 37849 in rats. Pharmacol Biochem Behav 55:163-168.
68. Zajaczkowski W, Quack G, Danysz W (1996b). Infusion of (+)-MK-801 and memantine - contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 296:239-246.